cryptotanshinone has been researched along with Psoriasis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Debnath, B; Neamati, N; Xu, S | 1 |
Feng, B; He, S; Li, C; Liu, B; Liu, H; Lu, C; Su, Z; Tang, L; Wang, X; Xu, F; Zhao, J; Zheng, G; Zheng, X; Zhu, W; Zhu, Y | 1 |
1 review(s) available for cryptotanshinone and Psoriasis
Article | Year |
---|---|
Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; High-Throughput Screening Assays; Humans; Neoplasms; Peptides; Peptidomimetics; Psoriasis; Signal Transduction; STAT3 Transcription Factor; Stem Cells; Structure-Activity Relationship | 2012 |
1 other study(ies) available for cryptotanshinone and Psoriasis
Article | Year |
---|---|
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drugs, Chinese Herbal; Epidermis; Humans; Hyperplasia; Imiquimod; Keratinocytes; Male; Mice, Inbred C57BL; Phenanthrenes; Psoriasis; STAT3 Transcription Factor | 2018 |